COVID-19 Pilot Infusion Treatment
El Paso is providing the new COVID-19 treatment called Bamlanivimab, in an effort to prevent hospitalizations due to the progress of severe symptoms in high risk patients.
El Paso was selected to provide this treatment modality of monoclonal antibody developed by Eli Lilly due to the high number of COVID-19 positive cases and hospitalizations. El Paso has received a limited number of doses of this new infusion treatment.
Bamlanivimab is not authorized for patients who are already hospitalized or require oxygen therapy due to COVID-19.
The FDA has granted the emergency use of Bamlanivimab, which is medication used for the treatment of COVID-19 in patients who meet the following criteria:
- COVID-19 positive
- Non-hospitalized adults and adolescents 12 years of age and older
- Mild to moderate symptoms
- Weigh 88 pounds or more (high BMI over 35 for adults or over the 85th percentile for a child’s age and gender based on the CDC growth charts)
- Underlying health conditions (chronic kidney disease, diabetes, immunosuppressive disease, cardiovascular disease, hypertension, respiratory disease, or other)
- High risk for developing severe COVID-19 symptoms
High risk is defined as patients who meet at least one of the following criteria:
- COVID-19 positive
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
- cardiovascular disease, OR
- hypertension, OR
- chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 – 17 years of age AND have
- BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR
- sickle cell disease, OR
- congenital or acquired heart disease, OR
- neurodevelopmental disorders, for example, cerebral palsy, OR
- Muscular dystrophy or SMA, OR
- a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.
Patients who qualify for the treatment receive a one-time intravenous (or IV) dose that takes about 1 hour to infuse. Patients will be required to wait an additional hour to monitor the reaction to the treatment.
Patients who have tested positive for COVID-19 and meet the criteria may be screened at participating clinics. Participating clinics are currently being brought on board, and will be added to the list below:
|
Centro San Vicente Clinics |
8061 Alameda Ave. |
915-859-7545 |
|
|
La Fe Care Centers |
1505 Mescalero Dr. |
915-772-3366 |
|
|
Project Vida |
3612 Pera Ave. |
915-533-7057 |
|
|
Texas Tech Clinics – Internal Medicine |
4801 Alberta Ave. |
915-215-5200 |
|
|
Texas Tech Clinics – Kenworthy |
9839 Kenworthy St. |
915-215-5500 |
|
|
Texas Tech Clinics – Trans Mountain |
2000-B Trans Mountain Dr. |
915-215-8400 |
|
|
UMC Neighborhood Center East |
1521 Joe Battle Blvd. |
915-975-8900 |
By appointment only |
|
UMC Neighborhood Center Fabens |
101 Potasio; Fabens, Texas |
915-975-8900 |
By appointment only |
|
UMC Neighborhood Center West |
6600 N. Desert Blvd. |
915-975-8900 |
By appointment only |
|
UMC Neighborhood Center Ysleta |
300 S. Zaragoza Rd. |
915-975-8900 |
By appointment only |
|
Upper Valley Urgent Care Center |
121 Redd Rd. |
915-584-8882 |
|
|
MedPost Cimarron |
7480 Paseo del Norte, El Paso, TX 79912 |
(915) 308-2060 |
|
|
MedPost Kenworthy |
10765-A Kenworthy St, El Paso, TX 79924 |
(915) 320-4021 |
|
|
MedPost North Zaragoza |
1801 N Zaragoza Rd, El Paso, TX 79936 |
(915) 249-3106 |
|
|
MedPost Edgemere Kids |
12371 Edgemere Blvd #207, El Paso, TX 79938 |
(915) 856-0008 |
|
|
MedPost Viscount |
9100 Viscount Blvd, El Paso, TX 79925 |
(915) 594-4475 |
|
|
MedPost Sunland Park |
601 Sunland Park Dr, El Paso, TX 79912 |
(915) 577-8223 |
Patients treated with Bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to Local Health Orders and CDC guidelines.
More information can be found in the Federal Drug Administration’s Fact Sheet (Lea la hoja informativa en español).